151 related articles for article (PubMed ID: 35581731)
1. Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis.
Kim Y; Cho NY; Kang GH
J Pathol Transl Med; 2022 May; 56(3):144-151. PubMed ID: 35581731
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and prognostic significance of Fusobacterium nucleatum infection in colorectal cancer: a meta-analysis.
Huangfu SC; Zhang WB; Zhang HR; Li Y; Zhang YR; Nie JL; Chu XD; Chen CS; Jiang HP; Pan JH
J Cancer; 2021; 12(6):1583-1591. PubMed ID: 33613745
[No Abstract] [Full Text] [Related]
3. Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers.
Chen Y; Lu Y; Ke Y; Li Y
Medicine (Baltimore); 2019 Sep; 98(39):e17221. PubMed ID: 31574832
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of
Xie Y; Jiao X; Zeng M; Fan Z; Li X; Yuan Y; Zhang Q; Xia Y
Cancer Manag Res; 2022; 14():3021-3036. PubMed ID: 36262751
[TBL] [Abstract][Full Text] [Related]
5. Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer.
Lee DW; Han SW; Kang JK; Bae JM; Kim HP; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Ann Surg Oncol; 2018 Oct; 25(11):3389-3395. PubMed ID: 30062471
[TBL] [Abstract][Full Text] [Related]
6. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
7. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.
Kunzmann AT; Proença MA; Jordao HW; Jiraskova K; Schneiderova M; Levy M; Liska V; Buchler T; Vodickova L; Vymetalkova V; Silva AE; Vodicka P; Hughes DJ
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1891-1899. PubMed ID: 31367996
[TBL] [Abstract][Full Text] [Related]
8.
Gethings-Behncke C; Coleman HG; Jordao HWT; Longley DB; Crawford N; Murray LJ; Kunzmann AT
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):539-548. PubMed ID: 31915144
[TBL] [Abstract][Full Text] [Related]
9. Fusobacterium Nucleatum Is a Risk Factor for Metastatic Colorectal Cancer.
Chen WD; Zhang X; Zhang YP; Yue CB; Wang YL; Pan HW; Zhang YL; Liu H; Zhang Y
Curr Med Sci; 2022 Jun; 42(3):538-547. PubMed ID: 35678912
[TBL] [Abstract][Full Text] [Related]
10. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population.
Yamaoka Y; Suehiro Y; Hashimoto S; Hoshida T; Fujimoto M; Watanabe M; Imanaga D; Sakai K; Matsumoto T; Nishioka M; Takami T; Suzuki N; Hazama S; Nagano H; Sakaida I; Yamasaki T
J Gastroenterol; 2018 Apr; 53(4):517-524. PubMed ID: 28823057
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II/III Colorectal Cancers Treated with Adjuvant Chemotherapy.
Oh HJ; Kim JH; Bae JM; Kim HJ; Cho NY; Kang GH
J Pathol Transl Med; 2019 Jan; 53(1):40-49. PubMed ID: 30586952
[TBL] [Abstract][Full Text] [Related]
12. Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients.
Boehm ET; Thon C; Kupcinskas J; Steponaitiene R; Skieceviciene J; Canbay A; Malfertheiner P; Link A
Sci Rep; 2020 Oct; 10(1):16240. PubMed ID: 33004953
[TBL] [Abstract][Full Text] [Related]
13. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.
Ito M; Kanno S; Nosho K; Sukawa Y; Mitsuhashi K; Kurihara H; Igarashi H; Takahashi T; Tachibana M; Takahashi H; Yoshii S; Takenouchi T; Hasegawa T; Okita K; Hirata K; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
Int J Cancer; 2015 Sep; 137(6):1258-68. PubMed ID: 25703934
[TBL] [Abstract][Full Text] [Related]
14. Involvement of
He Z; Tian W; Wei Q; Xu J
Front Immunol; 2022; 13():968649. PubMed ID: 36059542
[No Abstract] [Full Text] [Related]
15. Diagnostic Performance of Intestinal
Peng BJ; Cao CY; Li W; Zhou YJ; Zhang Y; Nie YQ; Cao YW; Li YY
Chin Med J (Engl); 2018 Jun; 131(11):1349-1356. PubMed ID: 29786050
[TBL] [Abstract][Full Text] [Related]
16. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
Yang Y; Weng W; Peng J; Hong L; Yang L; Toiyama Y; Gao R; Liu M; Yin M; Pan C; Li H; Guo B; Zhu Q; Wei Q; Moyer MP; Wang P; Cai S; Goel A; Qin H; Ma Y
Gastroenterology; 2017 Mar; 152(4):851-866.e24. PubMed ID: 27876571
[TBL] [Abstract][Full Text] [Related]
17. Association of Fusobacterium nucleatum infection with the clinicopathological characteristics in colorectal cancer patients.
Pang SW; Armon S; Chook JB; Chew J; Peh KB; Lim WW; Peh SC; Teow SY
Mol Biol Rep; 2024 Jan; 51(1):124. PubMed ID: 38227097
[TBL] [Abstract][Full Text] [Related]
18. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Mima K; Sukawa Y; Nishihara R; Qian ZR; Yamauchi M; Inamura K; Kim SA; Masuda A; Nowak JA; Nosho K; Kostic AD; Giannakis M; Watanabe H; Bullman S; Milner DA; Harris CC; Giovannucci E; Garraway LA; Freeman GJ; Dranoff G; Chan AT; Garrett WS; Huttenhower C; Fuchs CS; Ogino S
JAMA Oncol; 2015 Aug; 1(5):653-61. PubMed ID: 26181352
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological differences of high
Wang Y; Wen Y; Wang J; Lai X; Xu Y; Zhang X; Zhu X; Ruan C; Huang Y
Front Microbiol; 2022; 13():945463. PubMed ID: 36406461
[TBL] [Abstract][Full Text] [Related]
20. Colon Cancer-Associated
Abed J; Maalouf N; Manson AL; Earl AM; Parhi L; Emgård JEM; Klutstein M; Tayeb S; Almogy G; Atlan KA; Chaushu S; Israeli E; Mandelboim O; Garrett WS; Bachrach G
Front Cell Infect Microbiol; 2020; 10():400. PubMed ID: 32850497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
